PD ‐L1 testing for lung cancer in the UK : recognizing the challenges for implementation-Reference-Cited by-同舟云学术

PD ‐L1 testing for lung cancer in the UK : recognizing the challenges for implementation

Published:2016-06-30 Issue:2 Volume:69 Page:177-186
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Cree Ian A¹,Booton Richard²,Cane Paul³,Gosney John⁴,Ibrahim Merdol⁵,Kerr Keith⁶,Lal Rohit⁷,Lewanski Conrad⁸,Navani Neal⁹,Nicholson Andrew G¹⁰,Nicolson Marianne¹¹,Summers Yvonne¹²

Affiliation:

1. Department of Pathology University Hospitals Coventry and Warwickshire NHS Trust Coventry UK

2. Respiratory and Allergy Research Group Institute of Inflammation & Repair North West Lung Centre University of Manchester University Hospital of South Manchester NHS Foundation Trust Manchester UK

3. Department of Histopathology Guy's and St Thomas' NHS Foundation Trust London UK

4. Department of Pathology Royal Liverpool and Broadgreen University Hospitals NHS Trust Liverpool UK

5. UK National External Quality Assessment Service for Immunocytochemistry and In Situ Hybridisation London UK

6. Department of Pathology Aberdeen Royal Infirmary/Aberdeen University Medical School Aberdeen UK

7. Guy's and St Thomas' NHS Foundation Trust London UK

8. Oncology Department Charing Cross Hospital Imperial College Healthcare NHS Trust London UK

9. Lungs for Living Research Centre UCL Respiratory University College London Hospitals NHS Foundation Trust London UK

10. Royal Brompton and Harefield Hospitals NHS Foundation Trust and National Heart and Lung Division Imperial College London UK

11. Department of Oncology NHS Grampian Aberdeen Royal Infirmary Aberdeen UK

12. The Christie Hospital NHS Foundation Trust Manchester UK

Funder

Imperial College London

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/his.12996

Reference28 articles.

1. Globocan2012.Lung cancer: estimated incidence mortality and prevalence worldwide in 2012. Available at:http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx(accessed 3 May 2016).

2. Royal College of Physicians.National Lung Cancer Audit annual report 2014. Available at:https://www.rcplondon.ac.uk/projects/outputs/nlca-annual-report-2014(accessed 3 May 2016).

3. Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)

4. The role of molecular pathology in non‐small‐cell lung carcinoma—now and in the future;Brandao GD;Curr. Oncol.,2012

5. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein-based biomarkers in pulmonary malignancies;Diagnostic Histopathology;2024-07

2. A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy;Clinical Oncology;2024-03

3. Optimizing tissue stewardship in non‐small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists;Histopathology;2023-11-13

4. Aspectos prácticos sobre la determinación de PD-L1 en el tratamiento de carcinoma urotelial. Consenso del grupo de uropatología de la SEAP;Revista Española de Patología;2023-10

5. Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones;Modern Pathology;2023-09